Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
payday loans today
Popular Articles
Burdock Root

Quinine Side Effects May Be Result Of Tryptophan Deficiency
Researchers have found that the anti-malarial drug quinine can block a cell"s ability to take up the essential amino acid tryptophan, a discovery that may explain many of the adverse side-effects associated with quinine. Once confirmed, these findings would suggest that dietary tryptophan supplements could be a simple and inexpensive way to improve the performance of this important drug.
generic viagra online
President Obama Picks New York City Health Commissioner Thomas Frieden For CDC Director
President Obama on Friday appointed New York City Health Commissioner Thomas Frieden as CDC director, according to Obama administration officials, the New York Times reports. According to the Times, Frieden, an infectious disease specialist, has "cut a high and sometimes contentious profile" in his seven years as health commissioner in New York City, during which time he has advocated for a smoking ban in restaurants and bars, made HIV testing part of routine medical exams and protected a program that distributes 35 million condoms a year. According to the Times, Frieden is expected to take office next month. The Times reports that he will "inherit a host of immediate and long-term problems," including questions surrounding a vaccine for the H1N1 influenza virus, also known as swine flu, health care reform and organizational issues at CDC.The Times reports that a potential advantage for Frieden is a positive relationship with likely FDA Commissioner Margaret Hamburg, who also was New York City health commissioner. Frieden would work with Hamburg to combat the H1N1 flu virus and to re-evaluate the U.S. food safety system (Harris/Hartocollis, New York Times, 5/15).
News of the day
Journal Of Obstetrics And Gynecology Of India, Largest Circulation Medical Journal In India, Joins Springer Program
Springer, one of the leading publishers in the field of science, technology and medicine, has signed a cooperation agreement with the Federation of Obstetric and Gynaecological Societies of India (FOGSI) to publish The Journal of Obstetrics and Gynecology of India (JOGI).
Diagnostics

Stem Cell Therapeutics Receives Clearance From Health Canada To Proceed With The Phase IIb Clinical Stroke Trial

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS)("SCT" or "the Company") has received a No Objection Letter ("NOL") from Health Canada for the modified REGENESIS protocol using NTx®-265 for a Phase IIb clinical trial treating acute ischemic stroke. Dr. Alan Moore, President and CEO, commented as follows: "We are pleased that Health Canada has issued an NOL for the modified REGENESIS clinical trial. This welcome development means that we are able to proceed with recruitment of patients, testing the NTx®-265 regimen in patients with acute ischemic stroke in Canada again and demonstrating the ability of this novel approach to speed recovery from stroke disabilities. This satisfying development can be directly attributed to the perseverance and strong belief of all the SCT staff that NTx®-265 will, in the future, redefine the therapies available to patients recovering from acute ischemic stroke, traumatic brain injury, and neurological disease." About REGENESIS (a Phase II prospective, randomized, double-blind, placebo controlled study of NTx®-265: hCG and epoetin alfa in acute ischemic stroke patients): NTx®-265 is SCT"s lead therapeutic regimen of two approved and clinically well-defined drugs, human Chorionic Gonadotropin ("hCG") and Erythropoietin ("EPO"), targeting the treatment of stroke. The twin objectives of the treatment are to stimulate the growth and differentiation of new neurons to replace the brain cells that were lost or damaged by the stroke, and importantly, to direct motor, visual, and cognitive recovery after the acute ischemic stroke. Encouraging clinical results from SCT"s BETAS Phase IIa stroke trial were presented at the International Stroke Conference in February 2009, showing clinically relevant recovery in 12 of 12 patients who received the complete treatment. SCT received clearance from the FDA to proceed with the Phase IIb stroke trial on May 15, 2009. Stem Cell Therapeutics Corp.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009